Remix Therapeutics announced today that it is officially launching with $81 million in financing. The funds will be used to support the development of the company’s REMaster technology platform. In addition, Remix will now be able to advance its pipeline of RNA processing targeted therapeutics as well.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,